Targeted Protein Degradation Market Size, Strategic Analysis, Growth Drivers, Industry Trends, Demand and Future Opportunities and Forecast Period
The targeted
protein degradation (TPD) market is anticipated to reach USD XXX.X
million by 2034 from USD XXX.X million in 2023, at a CAGR of XX.X% during the
forecast period 2024-2034.
Drugs that target proteins that were previously deemed
"undruggable" due to the lack of optimal binding sites appropriate
for small molecule inhibitors can benefit greatly from this strategy. Using the
ubiquitin-proteasome system (UPS) or lysosomal degradation pathways to break
down undesirable proteins is the fundamental mechanism of TPD.
Request
For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/targeted-protein-degradation-market
The majority of it is carried out by forward degraders such
as Molecular Glues, Proteolysis Targeting Chimeras (PROTACs), and Lysosome
Targeting Chimeras (LYTACs). The market for targeted protein degradation (TPD)
has grown significantly in the last several years. The primary causes of the
expansion include the rising rates of chronic illness around the world,
advancements in proteomics, and significant investments in the research and
development of protein degradation technologies.
Growth Drivers:
The growing prevalence of neurological disorders and cancer
worldwide is a key factor propelling the market for targeted protein
degradation. For example, the International Agency for Research on Cancer
(IARC) estimates that 9.7 million people died from cancer and 20 million new
cases were diagnosed in 2022. With 2.5 million new cases, or 12.4% of all new
cases, lung cancer was the most frequent cancer in the world. Female breast
cancer came in second with 2.3 million new cases, or 11.6% of all new cases.
The market for targeted protein degradation has grown
significantly due to advancements in biotechnology and medication discovery.
Novel strategies, including autophagy-targeting chimeras (AUTACs),
lysosome-targeting chimeras (LYTACs), proteolysis-targeting chimeras (PROTACs),
and molecular glues, have improved TPD's capacity to specifically eradicate
disease-causing proteins.
Targeted Protein
Degradation Segmentation:
By Degrader Type:
· Proteolysis-Targeting
Chimeras (PROTACs)
· Lysosome-Targeting
Chimeras (LYTACs)
· Autophagy-Targeting
Chimeras (AUTACs)
· Selective
Estrogen Receptor Degraders (SERDs)
· Molecular
Glues
· Others
By Indication:
· Oncology
o Breast
Cancer
o Multiple
Myeloma
o Others
· Neurology
· Others
By End-User:
· Hospitals
& Clinics
· Pharmaceutical
& Biotechnology Companies
· Academic
& Research Institutes
· Others
By Region:
· North
America
· Europe
· Asia
Pacific
· Latin
America
· Middle
East and Africa
Key Companies
in Targeted Protein Degradation Market:
The research report
offers a competitive analysis of prominent companies operating in the global
targeted protein degradation market. Some of the leading players
profiled in the market research report include:
· Arvinas
· AstraZeneca
· Bristol-Myers
Squibb Company
· C4
Therapeutics, Inc.
· Ranok
Therapeutics Co. Ltd.
· Nurix
Therapeutics, Inc.
· Foghorn
Therapeutics
· Kymera
Therapeutics, Inc.
· Lycia
Therapeutics
· Kangpu
Biopharmaceuticals.
· Biotheryx,
Inc.
· Other
Player’s
For
More Information about this Report @ https://www.xresearch.biz/shop/targeted-protein-degradation-market
About
Us: -
xResearch is a market research and consulting organization that
uses unique data, expert analysis, and new technologies to create trusted
intelligence on industries. Our research is focused on delivering an informed
and impartial view on essential market data of industry, and it is primarily
driven by an in-depth study covering the following parameters: Market Sizing
and Forecasting, Market Segmentation, Competitive Analysis, Strategic
Assessment and Business Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-619-8140
Websites:
https://www.xresearch.biz/

Comments
Post a Comment